NCT06058182 RNA as Prognostic Biomarkers in Patients With Acute Coronary Syndrome
| NCT ID | NCT06058182 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Policlinico S. Donato |
| Condition | Coronary Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 70 participants |
| Start Date | 2020-07-13 |
| Primary Completion | 2026-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70 participants in total. It began in 2020-07-13 with a primary completion date of 2026-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Identify circulating protein-coding (mRNAs) or non-coding (ncRNAs) transcripts (ACS\_signature) predictive of ventricular dysfunction in ACS patients undergoing PCI.
Eligibility Criteria
Inclusion Criteria: 1. Age \>18 years 2. Patients with ACS (first episode), defined according to the guidelines of the European Society of Cardiology (ESC) 2017 3. Indication for percutaneous revascularization treatment 4. Informed consent to study enrollment Exclusion Criteria: 1. Severe valve disease or other conditions requiring cardiac surgery 2. Previous cardiac surgery including coronary artery bypass grafts 3. Total chronic occlusions 4. Patients with known hypersensitivity or contraindication to any of the following drugs: * heparin * aspirin, * clopidogrel, * ticlopidine, * sirolimus, * everolimus. 5. Any contraindication to drug-eluting stent implantation (DES) 6. Patients with a documented history of myocardial infarction; 7. Left ventricular ejection fraction (LVEF) \<30% before PCI 8. Patients in cardiogenic shock 9. Patients with advanced ST-segment elevation myocardial infarction (\> 48 h from onset of symptoms/Q waves on electrocardiogram) or undergoing fibrinolysis; 10. Patients with prior known cardiomyopathy with LVEF \< 40% 11. Patients with malignant neoplasm or systemic disease with quoad vitam prognosis less than 1 year; 12. Patients with known active infectious diseases; 13. Patients who are unable to express valid informed consent to the act of enlistment 14. Pregnant women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06058182 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06058182 currently recruiting?
Yes, NCT06058182 is actively recruiting participants. Contact the research team at luca.testa@grupposandonato.it for enrollment information.
Where is the NCT06058182 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06058182 clinical trial?
NCT06058182 is sponsored by IRCCS Policlinico S. Donato. The trial plans to enroll 70 participants.